Amphastar receives fda approval for ganirelix acetate injection

Rancho cucamonga, ca / accesswire / april 8, 2022 / amphastar pharmaceuticals, inc., (nasdaq:amph) announced that the u.s. food and drug administration ("fda") has approved the company's abbreviated new drug application ("anda") for ganirelix acetate injection, 250mg/0.5ml in a prefilled syringe. ganirelix acetate injection is indicated for the inhibition of premature luteinizing hormone (lh) surges in women undergoing controlled ovarian hyperstimulation.
AMPH Ratings Summary
AMPH Quant Ranking